Aptamers are chemically synthesized single-standard oligonucleotides. Aptamers offer relative cost advantage and are developed through more reliable process than monoclonal antibodies. The global aptamer market was valued approximately US$ 1.0 Bn in 2016 and is anticipated to register CAGR of over 20.0% from 2017 to 2025 to reach value of approximately US$ 5.0 Bn by 2025. Advancement in technologies for selection of aptamer and increasing interest of research scientists in the field of aptamer technology owing to various advantages over antibodies are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335
Inadequate Regulatory Policies and Ethical Issues Related To Aptamer Development Can Restrain Global Market Expansion
Aptamer can be used as alternative to antibodies for various application. There is no formal regulatory guideline, which specifically addresses the quality expectation of aptamers. The regulatory expectation of aptamer-based drugs is still evolving. Several countries in Europe have tedious documentation processes for starting clinical trials of aptamers. For example, in Europe, the EU Clinical Trial Directive 2001/20/ EC is mandatory for initiation of aptamer clinical trials. However, the region has not developed any oligonucleotide specific guideline that can address the general requirements for the quality of aptamer clinical trials. Moreover, lack of universal rules for the application of aptamers in bioassays, which is well established when working with antibodies, restrains growth of global aptamer market.
Other Selection Techniques (e.g. X- Aptamer, MARAS etc.) to Lose Market Share
The report offers detailed segmentation of global aptamers market based on material type, selection technique and applications. Among the selection technique studied, SELEX technique segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. SELEX technique is likely to get boost for the modification of existing SELEX process, and available of the new updated SELEX technique like CE-SELEX, M- SELEX etc. which overcome the certain limitation for aptamer selection. The other technique (X-aptamer, MARAS technique etc.) segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of ~18.0% by 2025 from ~21% in 2016. Availability of upgraded SELEX technique and lack of selection of high affinity ligands as compare to SELEX technique are factors likely to hamper this segment.